Search Results for "Hmpl 004"
Original Source: Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine.
Background Andrographis paniculata is an herbal mixture used to treat inflammatory diseases. An extract of the herb, HMPL-004, inhibits TNF-α and IL-1β, and prevents colitis in animal models. Aim To determine the efficacy and safety of HMPL-004 in patients with mild-to-moderate ulcerative colitis. Methods A randomised, double-blind, multicentre, 8-week parallel group study was conducted using HMPL-004 1200 mg/day compared with 4500 mg/day of slow release mesalazine (mesalamine) granules in pa...
Matching Channels
None
Matching News
Hutchison MediPharma Releases Phase I Data on Two Cancer Molecules
Hutchison MediPharma, the innovative China drug company that is majority owned by Chi-Med, released positive Phase I data for its two most advanced cancer-targeting molecules: Sulfatinib (HMPL-012)...
Chi-Med and Nestlé Form JV to Develop Chi-Med’s Lead Drug Candidate
Hutchison Chi-Med and Nestlé announced the formation of a major new JV based on Chi-Med’s expertise in traditional Chinese medicines. The JV, which will be called Nutrition Science Part...
A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&...
Andrographis paniculata plant extract helps ulcerative colitis
NEW YORK (Reuters Health) - A purified extract from the Andrographis paniculata plant (HMPL-004) increases remission rates in patients with mildly to moderately active ulcerative colitis.
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&...
Hutchison MediPharma Starts Clinical Trial on Fourth Cancer Drug
Hutchison MediPharma, the drug discovery arm of China MediTech, has begun a Phase I clinical trial of Theliatinib (HMPL-309) in patients with non-small cell lung cancer. The drug is a small molecule...
Chi-Med, Nestle to form JV for plant-based products
Hutchison China MediTech Ltd. (LSE:HCM) and the Nestle Health Science S.A. subsidiary of Nestle S.A. (SIX:NESN) are forming a 50/50 JV, Nutrition Science Partners Ltd., to develop and commercialize wo...
Matching PubMed Articles
Background Andrographis paniculata is an herbal mixture used to treat inflammatory diseases. An extract of the herb, HMPL-004, inhibits TNF-α and IL-1β, and prevents colitis in animal models. Aim...
Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis.
OBJECTIVES:Andrographis paniculata has in vitro inhibitory activity against TNF-α, IL-1β and NF-κB. A pilot study of A. paniculata extract (HMPL-004) suggested similar efficacy to mesalamine for ul...
